Methylphenidate Xiromed (Methylphenidate Hydrochloride)

Methylphenidate blocks the reuptake of dopamine and norepinephrine, increasing their levels in the brain. This heightened neurotransmitter activity enhances alertness, focus, and impulse control, which underlies its therapeutic effects.

The dosage of Methylphenidate Xiromed is individualized by the prescribing clinician based on the patient’s age, condition, and response. Only a qualified health professional should determine the appropriate dose.

Methylphenidate Xiromed is classified as Pregnancy Category C, indicating that risk cannot be ruled out. It should be used only if the potential benefit justifies the potential risk. Breastfeeding mothers should consult their doctor, as the drug can pass into milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methylphenidate Xiromed belongs to the central nervous system stimulant class, similar to other methylphenidate products and amphetamine‑based therapies. Compared with non‑stimulant options, it generally has a faster onset of action but may carry a higher risk of cardiovascular and psychiatric side effects.

Store Methylphenidate Xiromed at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, heat and direct sunlight to maintain stability.

Methylphenidate Xiromed is taken orally, usually as a tablet or capsule, as directed by the prescriber. It should be swallowed whole with water and taken at the prescribed times, often in the morning to reduce the risk of insomnia.

Serious risks include cardiovascular events such as hypertension or tachycardia, emergence of psychotic symptoms like hallucinations, and severe allergic reactions (anaphylaxis). Patients should be monitored closely for these events, especially during treatment initiation.

Methylphenidate Xiromed should be avoided in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors, patients with severe cardiovascular disease, and persons with a history of serious psychiatric disorders unless specifically evaluated by a specialist.